Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2846592

O=C(O)C(F)(F)F.O=C(O)CCc1ccnc2ccccc12

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.46
FFAR4 Q5NUL3 1/20 0.44
PARP1 P09874 2/20 0.43
PARP2 Q9UGN5 1/20 0.43
KMT2A Q03164 2/20 0.42
SIRT5 Q9NXA8 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
FAAH O00519 1/20 0.41
CASP1 P29466 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
IDO1 P14902 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
KEAP1 Q14145 1/20 0.40
FLT1 P17948 2/20 0.39
KDR P35968 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1650885 0.92 CYP1A2 (0.55) CYP1A2LOXL2PARP1PARP2KMT2A
SCHEMBL5273635 0.83 CYP1A2 (0.52) CYP1A2LOXL2PARP1PARP2KMT2A
SCHEMBL5210378 0.82 CYP1A2 (0.51) CYP1A2LOXL2KMT2AHDAC6
SCHEMBL2846594 0.81 CYP1A2 (0.42) CYP1A2LOXL2FAAHIDO1ADORA2A
SCHEMBL7832661 0.81 MAPT (0.51) CYP1A2LOXL2
SCHEMBL7829170 0.81 MAPT (0.51) CYP1A2LOXL2
SCHEMBL5514406 0.78 LOXL2 (0.51) CYP1A2LOXL2FAAHCASP1KDM4E
Trifluoroacetic Acid SCHEMBL20562445 0.77 CYP19A1 (0.43) LOXL2KMT2ACASP1KDM4EL3MBTL1
Quinolin-4-Amine SCHEMBL8908513 0.77 NCF1 (0.68) CYP1A2LOXL2KMT2AL3MBTL1ADORA2A
SCHEMBL1703912 0.77 LMNA (0.43) CYP1A2PARP1PARP2HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152670-B1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2013-12-25 EP disclosed
US-8202885-B2 Bridged six-membered ring compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-06-19 US disclosed
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2010-05-27 US disclosed
EP-2152670-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2010-02-17 EP disclosed
WO-2008132679-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS CACNA1E, CACNA1B, CACNA1A CYP1A2 905/4885LOXL2 4110/4885FFAR4 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.